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Abstract--We studied the occurrence of T-cell subpopulations for patients with B-cell chronic 
lymphocytic leukemia. The CD8 ÷ population was divided into CD8 ÷ suppressor (CD8a ÷) and CD8 ÷ 
cytotoxic (CD8b ÷) lymphocytes u ing difference in orthogonal light scattering. 
Average CD4÷/CD8+ratios determined for all patients were decreased. For individual patients this 
sometimes was not true. In contrast CD4÷/CD8a +ratios were markedly increased in all individual 
patients. The CD8 ÷ lymphocytes appeared to consist mainly of CD8b+lymphocytes. Moreover the 
CD8b+/CD8 ÷ratio correlated with clinical stage: untreated patients (stage 0 of Rai) have smaller 
CD8b+/CD8 +ratios than patients with advanced stages of Rai. 
Key words: B-chronic lymphocytic leukemia (B-CLL), leukemia, white blood cells, leukocytes, 
suppressor lymphocytes, cytotoxic lymphocytes. 
INTRODUCTION 
VARIOUS T-cell abnormalities have been reported for 
B-chronic lymphocytic leukemia (B-CLL) patients. 
Most authors describe an increase in CD8 positive 
lymphocytes (CD8 ÷) and a decrease in CD4 positive 
lymphocytes (CD4 ÷) [1-8]. Functional T-cell studies 
yield contradictory results; normal [9] or decreased 
helper function is described [10-12] as well as 
decreased [13] or increased suppressor function [14, 
15]. 
We have shown previously that using flow cyto- 
metry (FCM) two populations of lymphocytes can be 
distinguished by measuring the light scattering signal 
in the orthogonal direction [16]. It was demonstrated 
that these subpopulations consist of regulatory and B- 
lymphocytes (low orthogonal light scattering signal) 
and cytotoxic lymphocytes (high orthogonal ight 
scattering signal). In another eport we have shown 
that the CD8 + lymphocyte population could be div- 
ided in a suppressor- and a cytotoxic lymphocyte 
CD8 + subpopulation [17]. 
In this study we have used FCM to get more 
detailed insight in the occurrence of CD8 + suppressor 
and CD8 ÷ cytotoxic lymphocytes in peripheral blood 
of B-CLL patients. 
MATERIALS AND METHODS 
Patient populations 
The study included 22 patients with B-CLL with a mean 
age of 59 (range 41-85). The patients were graded using 
the Rai clinical staging [18]. Seven patients with stage 0 
with no progression for at least two years were included, 
one of them was previously treated because of severe 
disease (IV Rai). Four patients graded stage 0 in partial 
remission, all previously stage IV and successfully treated 
with chlorambucil sometimes in combination with 
prednisolone. These patients received maintenance treat- 
ment. Also included were four patients graded stage IV, 
two patients with stage III and one patient with stage II 
before receiving any treatment and four patients graded 
stage IV showing not or insufficient§ improvement after 
treatment ofat least one year with chlorambucil sometimes 
in combination with prednisolone. 
Preparation of lymphocytes 
Human blood was collected between 8 and 9 p.m. by 
venipuncture into vacutainer tubes containing heparin as 
anticoagulant (150 USP U sodium heparine/10 ml Veno- 
Abbreviations: B-CLL, B-cell chronic lymphocytic leu- 
kemia; FCM, flow cytometer; FITC-GAM, fluorescein so- 
thiocyanate labeled goat antimouse immunoglobulin. 
Correspondence to:Dr J. Greve, University of Twente, 
Dept of Applied Physics, Cell Characterization Group, 
P.O. Box 217, 7500 AE Enschede, The Netherlands. 
~No improvement is defined as no improvement of white 
blood and thrombocyte count as well as hemoglobin 
concentration. 
§Insufficient improvement is defined as a decrease in 
white blood cell count but no improvement of thrombocyte 
count and hemoglobin concentration, 
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ject Terumo Europe NV). Lymphocytes were obtained 
after density separation as described in detail elsewhere 
[17]. Lymphocytes were adjusted to a concentration of 
1.107 lymphocytes per ml with a standard buffer (PBS 
containing 0.05% sodium azide and 1% bovine serum 
albumin (BSA)). 
lmmunofluorescence 
The following monoclonal ntibodies (Mabs) were used: 
(a) unlabelled Mabs: CD8 (anti-leu2a, from Becton Dick- 
inson, Amersfoort, The Netherlands) T suppressor-cyto- 
toxic marker; CD4 (RIV 6, from National Institute for 
Public Health and Milieu (RIVM), Rijswijk, The Nether- 
lands) T helper-inducer marker; CD3 (RIV 3, from RIVM) 
pan T-cell marker; (b)fluorescein (FITC) labeled Mabs: 
CD3 (anti-leu4, from Becton Dickinson), CD4 (anti-leu3a, 
from Becton Dickinson); (c)phycoerythrine (PE) labeled 
Mab: CD8 (anti-leu2a, from Becton Dickinson). For 
second step reagents FITC conjugated goat antimouse 
immunoglobulin (FITC GAM) (Central Laboratory of 
Blood Transfusion Service (CLB) Amsterdam, The 
Netherlands) was used. All reagents were pretitered by 
using normal ymphocytes todetermine optimal conditions 
for binding. One hundred microliters of cell suspension 
was incubated with 20 fxl diluted Mab. Mabs were diluted 
in standard buffer for 30 min at room temperature. For 
indirect fluorescence the cells were washed twice with 
standard buffer and resuspended in 100 p,l diluted second 
step reagent. The cells were incubated for 30 min at room 
temperature. After incubation the cells were washed twice 
and resuspended in 1-ml standard buffer and kept on ice 
until use. 
Flow cytometric analysis was performed the same day to 
preserve both optimal binding of monoclonal ntibody and 
light scatter properties of lymphocytes [19, 20]. 
Flow cytometry measurements 
The FCM was described in detail elsewhere [17]. A 3- 
W argon ion laser tuned at 488 nm operating at a light 
intensity of 100mW was used. FITC emission was 
measured with a six-cavity bandfilter (510-550 nm, Pomfret 
Research Optics, Inc., Stanford, CT, U.S.A.). The PE 
emission was measured with an OG 570 colored glass filter 
(Schott, Tiel, The Netherlands). Reproducible apparatus 
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FIG. 1. Orthogonal light scatter histograms of CD8 ÷ lym- 
phocytes of four healthy donors (left) and four B-CLL 
patients (right). Note the two populations in orthogonal 
light scatter histograms of healthy donors whereas in B- 
CLL patients the same populations are present; however, 
the population showing a low orthogonal light scattering 
intensity is very small. Dashed lines are indicated at the 
positions of the maxima of the populations. 
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TABLE 1. RELEVANT CLINICAL DETAILS, PERCENTAGES OF CD3 +, CD4 +, CD8 ÷ LYMPHOCVTES AND CD8b+/ 
CD8 + RATIOS OF 22 B-CLL PATIENTS AND 30 HEALTHY CONTROLS 
553 
Lymphocyte % % % %CD8b 
Patient Sex/age Rai stage Treatment count x 106/ml CD3 CD4 CD8 CD8 
1 M85 0 No 81.0 2.4 1.7 2.2 74 
2 F56 0 No 74.6 23.4 8.3 4.4 88 
3 M86 0 No 97.6 3.9 1.8 2.4 79 
4 M77 0 No 13.6 11.1 10.4 2.2 70 
5 M41 0 No 39.0 9.1 7.6 2.7 84 
6 M68 0 No 37.0 7.7 4.9 1.8 87 
7 M54 0 No 5.9 25.9 17.4 8.0 87 
8 M46 0 Yes 2.3 48.3 16.2 31.2 98 
9 F70 0 Yes 3.4 31.8 9.8 19.8 99 
10 M56 0 Yes 15.9 42.0 20.1 18.7 95 
11 M50 0 Yes 16.0 16.7 5.8 5.8 97 
12 M52 II No 69.6 6.5 3.5 2.5 93 
13 F50 III No 261.0 1.5 0.7 0.7 94 
14 F59 III No 257.0 3.6 2.0 1.3 96 
15 M80 IV No 44.1 15.4 7.3 2.2 95 
16 M47 IV No 116.0 3.9 2.4 2.0 91 
17 M65 IV No 185.2 1.5 0.7 0.5 93 
18 M46 IV No 223.0 7.6 3.1 4.3 94 
19 M66 IV Yes 1.4 40.0 26.0 15.0 99 
20 M45 IV Yes 7.4 6.3 3.1 1.1 94 
21 M75 IV Yes 10.4 25.0 17.5 10.0 93 
22 M62 IV Yes 130.6 2.2 1.5 0.7 92 
range: 
min. 41 1.4 1.5 0.7 0.5 70 
max. 85 261.0 48.3 26.0 31.2 99 
mean 76.9 15.3 7.8 6.3 90.5 
- S.D. __.84.7 ---14.5 -+-7.2 +-8.0 ---7.8 
30 healthy controls 
range: 
min. 22 
max. 85 
mean 
+-. S.D. 
1.1 59 38 14 17 
4.3 86 66 28 69 
2.3 69.8 48.9 20.5 39.2 
0.7 5.7 6.5 3.8 11.9 
conditions for the measurement of light scatter histograms 
of lymphocytes were ensured by adjustment of the FCM 
with standard microspheres. Light scatter histograms of 
lymphocyte subpopulations were obtained after gating on 
the fluorescence intensity of immunofluorescently labeled 
cells. Gates are chosen such that cells are definitely 
positive: less than 0.01% of the cells of control samples fall 
within the gates. 
RESULTS 
Methodology 
Choice of stain. The relative number of T lym- 
phocytes in B-CLL patients can be reduced from 60 
to 80% of the total number of lymphocytes to 2% or 
less. In order to obtain reliable data on relative and 
absolute occurrence of the T-cell subsets amongst 
all lymphocytes one therefore has to study a large 
number of cells in a very selective way. 
With the monoclonal antibodies used CD3, CD4 
and CD8 the selectivity condition is met. In flow 
cytometry the presence of monoclonal antibodies on 
cell surfaces is detected with either direct or indirect 
immunofluorescence staining. We have compared 
direct and indirect immunofluorescence staining in 
order to investigate the possibility of detecting posi- 
tive cells that occur in a frequency below 1%. 
When using the direct immunofluorescence 
labeling, no reliable data can be obtained when posi- 
tive cells occur in a frequency of 2% or less, since 
1.3% of GAM stained lymphocytes are false positive. 
With direct immunofluorescence labeling using a 
fluorescently abeled irrelevant antibody (Igl-FITC) 
as control, down to 0-05% positive cells can be 
detected in a reliable way. All further data given in 
this paper were therefore obtained by using direct 
immunofluorescence labeling. 
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CD8a and CD8b determination 
Determination of CD8 + subpopulations was per- 
formed by dividing the orthogonal light scatter his- 
tograms into two components with a low (CD8a) and 
a large (CD8b) orthogonal light scattering signal as 
described in detail in earlier reports [16, 17]. In B- 
CLL patients the occurrence of both populations 
strongly differs from that of healthy donors as is 
shown in Fig. 1 for four patients and four controls. 
Dashed lines are indicated at the positions of the 
maxima of the two populations. In healthy controls 
two populations can be seen. In B-CLL patients the 
same populations are present, however, the popu- 
lation showing a low orthogonal light scattering inten- 
sity is very small. 
Therefore it may even be that for some B-CLL 
patients only the population with the large orthog- 
onal light scattering appears in the histograms. A 
large variation in the occurrence of CD8 + sub- 
populations of healthy donors is observed [17]. 
CD8b+/CD8 + ratios varied from 17 to 69 (mean 39). 
For individuals the variation in CD8b+/CD8 + ratios 
determined in a time period of 3 months is con- 
siderably less. We found a range of CD8b+/CD8 + 
ratios for one healthy donor of 24-40 (mean 36, n = 
5), for one B-CLL patient graded stage 0, a range 
of 74-79 (mean 76, n = 3) was found and for one B- 
CLL patient graded stage IV a range of 91-99 (mean 
95, n = 5) was found. No relation between CD8b+/ 
CD8 + ratio and age could be detected in the control 
group and the B-CLL patients. 
B-CLL patients 
Absolute number of T-cell subpopulations. The 
main clinical details of the patients and the results of 
the tests are shown in Table 1. The range, mean and 
standard eviations from the control group are shown 
at the bottom of the table. Lymphocyte counts for 
B-CLL patients varied considerably (range 1.4- 
261 × 106/ml). It is clear that CD3 +, CD4 + and CD8 ÷ 
percentages are lower than in healthy controls which 
is obviously due to the presence of the large number 
of B cells. The ratio of CD8b + to CD8 + lymphocytes 
(CD8b+/CD8 +) gives straightforward results: all 
patients are strongly abnormal compared with 
healthy donors (see also Fig. 3). For further eval- 
uation of the results the absolute number of CD3 +, 
CD4 + and CD8 + lymphocytes are presented in Fig. 
2. Although the mean values of the absolute number 
of CD3 +, CD4 + and especially CD8 + lymphocytes 
are increased no conclusive proof can be given for 
individual patients because of the very large patient 
to patient variation. 
Ratios of T-cell subpopulations. CD4+/CD8 + 
ratio's were calculated as well as the CD4+/CD8a ÷ 
ratios. They are presented in Fig. 3 together with the 
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FIG. 2. Absolute number o fCD3 + (a), CD4 + (b) and CD8 + 
lymphocytes (c) of 22 B-CLL patientes subdivided into 
clinical stage by Rai and presence (+)  or absence ( - )  
of treatment, compared with 30 healthy individuals (C). 
Lymphocyte counts are expressed on a logarithmic scale. 
The Kruskal-Wallis test showed that the data given for 
patients and healthy individuals are significantly different 
((a) p < 0.001, (b) p < 0.005 and (c) p < 0.0001). 
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FIG. 3. CD4+/CD8 + ratios (a), CD4+/CD8a +true helper/ 
suppressor ratios (b) and contribution of CD8 ÷ cytotoxic 
lymphocytes to the CD8 + population CD8b+/CD8 +(c), of 
22 B-CLL patients classified with the clinical staging model 
of Rai and presence or absence of treatment, compared 
with 30 healthy individuals (C). Note that the figures are 
on different scales. The Kruskal-Wallis test showed that 
the data given for patients and healthy individuals are 
significantly different ((a) p < 0.0005, (b) p < 0.00001 and 
(c) p < 0.00001). 
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ratio of CD8 + cytotoxic lymphocytes to all CD8 + 
lymphocytes (CD8b+/CD8+). 
Patients were subdivided in early and late disease 
as well as treated and untreated. The B-CLL group 
showed decreased mean CD4+/CD8 + values 
(1 .7 -  S.D. 1.0) compared with healthy donors 
(2.5 -+ S.D. 0.6) but a considerable number of indi- 
vidual CD4+/CD8 ÷ ratios fall within the normal 
range. When subdivided into clinical stages, stage IV 
patients on therapy all fall within the normal range 
whereas all treated stage 0 patients showed a sig- 
nificantly decreased CD4+/CD8 + ratio (Fig. 3a). 
When the CD4+/CD8a + ratios are determined a
completely new perspective is gained (Fig. 3b). 
CD4+/CD8a + ratios are strongly increased in the B- 
CLL group also when considered individually. 
Exceptions are the untreated stage 0 patients where 
two out of seven patients howed values overlapping 
with the normal individuals. Note the logarithmical 
scale. In Fig. 3c CD8b+/CD8 + ratios are given. All 
patients howed an increase in CD8b+/CD8 + com- 
pared with the control group. It is remarkable that 
untreated stage 0 CLL patients showed a smaller 
increase than the other patients. 
DISCUSSION 
The low frequency of T lymphocytes in B-CLL 
patients makes it very difficult to determine relative 
and absolute numbers of T-cell subpopulations. In
this study we demonstrate that using a flow cyto- 
meter, lymphocytes directly immunofluorescently 
labeled with monoclonal antibodies can be detected 
reliably even if they occur in a frequency down to 
0.05%. 
Most studies on T-cell subpopulations in B-CLL 
patients use T-cell enrichment by E-rosette formation 
and subsequent density separation for determination 
of T-cell subpopulations in B-CLL patients. Using 
this technique no accurate information on T-cell sub- 
populations i obtained because of variation in affin- 
ity during E-rosette formation, limited purity or 
enriched T cell and selective loss of T-cell sub- 
populations by enrichment [21]. Further compli- 
cations arise from E-rosette formation by 
immunoglobulin positive cells [22] and presence of E 
receptors in B-CLL cells [23]. To our knowledge only 
three studies have been reported in which direct 
assessment of T-cell subpopulations in B-CLL is per- 
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formed [2, 5, 8]. In these studies the median of the 
absolute number of T cells was enlarged especially 
of CD8 ÷ cells. Our results are in agreement with 
these studies (Fig. 2). However, a very large patient 
to patient variation is observed in absolute number 
of CD3 ÷, CD4 ÷ and CD8 ÷ lymphocytes. Absolute 
number of T cells can be increased up to 17 x 106/ 
ml. 
This could suggest monoclonal proliferation of T 
cells alongside the proliferating B cells. This is not 
the case however, because different T cell subsets, 
i.e. CD4 ÷, CD8 ÷, account for the increase. 
Concomitant with other reported studies [1-6] the 
mean CD4+/CD8 ÷ ratios in B-CLL patients is 
decreased (Fig. 3). However, it is not possible to 
draw conclusions from an individual CD4÷/CD8 ÷ 
ratio measured for a patient, since substantial overlap 
exists between CD4÷/CD8 ÷ ratios of controls and 
patients. No obvious relation with advancing disease 
as is reported by some authors [1, 3] could be found, 
except for patients showing no or insufficient 
improvement on treatment which all showed normal 
CD4÷/CD8 ÷ ratios. 
The CD4÷/CD8 ÷ ratio is often presented as 
helper/suppressor ratio. However, using this defi- 
nition heterogeneity of CD8 ÷ lymphocytes i not 
taken in consideration. In this study we have shown 
that with B-CLL patients this leads to completely 
wrong conclusions as becomes clear when CD4÷/ 
CD8a ratios are determined. This ratio more closely 
represents the helper/suppressor ratios [17]. The 
ratios are all strongly increased which suggest a rela- 
tive increase of helper lymphocytes instead of the 
assumed increase of suppressor lymphocytes. Only 
two patients with benign disease showed a normal 
CD4/CD8a ratio whereas for the other five patients 
the relative increase was less as compared with the 
other groups (Fig. 3b). 
With the determination f the CD4÷/CD8b ÷ratios 
a clear new view on T-cell subsets in B-CLL is 
revealed. No increase of suppressor lymphocytes is 
evoked by the proliferating B lymphocytes a is sug- 
gested by others [3], but an increase of CD8 ÷ cyto- 
toxic lymphocytes. This is clearly demonstrated by
the determination f the contribution of CD8 ÷ cyto- 
toxic lymphocytes tothe CD8 ÷ population (CD8b÷/ 
CD8 ÷) which is strongly increased in all B-CLL 
patients (Fig. 3c). Since the absolute number of 
CD8 ÷ lymphocytes was not decreased in B-CLL 
patients (Fig. 2c), the increase of CD8b÷/CD8 ÷is 
due to an increase of the absolute number of CD8b ÷ 
lymphocytes. An obvious relation with advancement 
of disease is found: all untreated stage 0 patients 
showed significantly less increased CD8b÷/CD8 +
ratio than patients on therapy and patients with 
advancing disease. The CD8b÷/CD8 ÷may be a par- 
ameter which can give an indication on prognosis or 
the results of treatment. (This is suggested by the 
well-known fact that prognosis of treated patients in 
partial remission isworse as compared with untreated 
stage 0 patients.) In agreement with this, one patient 
initially treated but in remission for three years had 
also a less increased CD8b÷/CD8 ÷ratio (patient 7, 
Table 1). The suggestion that increase in CD8 ÷ or 
Ty ÷ lymphocytes in B-CLL patients [1] is doubtful, 
since we have shown that this increase is merely 
due to increase of CD8 ÷ cytotoxic lymphocytes. An 
attractive alternative hypothesis i  that the hypo- 
gamma globulinaemia is due to a decrease of normal 
B lymphocytes. 
Support for an important influence of cytotoxic 
lymphocytes in B-CLL patients is given by studies 
where a significant increase of HNK-1 (leu7) lym- 
phocytes i found in B-CLL [8, 24]. Studies on helper 
and suppressor function in B-CLL patients give con- 
tradicting results. Increased [14, 15] or decreased [13] 
suppressor as well as increased [10-12] or normal [9] 
helper function are described. These contradictions 
could be caused by different methodology. It has to 
be noted that we have demonstrated that the CD8b ÷ 
lymphocytes in B-CLL patients have the physical 
properties and membrane r ceptor characteristics of 
cytotoxic lymphocytes. Our results uggest that func- 
tional studies of cytotoxic lymphocytes in B-CLL 
patients may be of great importance. The functional 
properties of these lymphocytes are still under 
investigation. An interesting hypothesis that the 
number of cytotoxic lymphocytes is increased in B- 
CLL patients because the immune system is involved 
in an active battle against he leukemic ells. If it is 
assumed that these cytotoxic ells are made because 
they are directed specifically against leukemic ells, 
the decreased cytotoxicity found in NK cell assays 
and antibody dependent cytotoxicity mediated assays 
in B-CLL patients is explained since in these assays 
the cytotoxicity for other cell types is tested [24-26]. 
If these hypothesis are true new prospectives for the 
understanding and treatment of leukemic diseases 
are revealed. 
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